These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 28000571

  • 1. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
    Talebi S, Bolhassani A, Azad TM, Arashkia A, Modaresi MH.
    Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
    [Abstract] [Full Text] [Related]

  • 2. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
    Mohit E, Bolhassani A, Zahedifard F, Taslimi Y, Rafati S.
    Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
    [Abstract] [Full Text] [Related]

  • 3. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
    Bolhassani A, Zahedifard F, Taghikhani M, Rafati S.
    Vaccine; 2008 Jun 19; 26(26):3362-70. PubMed ID: 18471945
    [Abstract] [Full Text] [Related]

  • 4. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
    Daemi A, Bolhassani A, Rafati S, Zahedifard F, Hosseinzadeh S, Doustdari F.
    Immunol Lett; 2012 Dec 17; 148(2):117-25. PubMed ID: 23085605
    [Abstract] [Full Text] [Related]

  • 5. Hp91 immunoadjuvant: An HMGB1-derived peptide for development of therapeutic HPV vaccines.
    Talebi S, Bolhassani A, Sadat SM, Vahabpour R, Agi E, Shahbazi S.
    Biomed Pharmacother; 2017 Jan 17; 85():148-154. PubMed ID: 27930979
    [Abstract] [Full Text] [Related]

  • 6. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
    Shahbazi S, Bolhassani A.
    Int Immunopharmacol; 2018 Sep 17; 62():170-180. PubMed ID: 30015237
    [Abstract] [Full Text] [Related]

  • 7. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH, Roden RBS, Wu TC, Chang YN, Hung CF.
    mBio; 2021 Jan 19; 12(1):. PubMed ID: 33468698
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S, Mohebbi A, Vakilzadeh G, Biglari P, Razeghi Jahromi S, Mohebi SR, Shirian S, Gorji A, Ghaemi A.
    Arch Virol; 2018 Mar 19; 163(3):587-597. PubMed ID: 29149434
    [Abstract] [Full Text] [Related]

  • 9. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.
    Mohit E, Bolhassani A, Zahedifard F, Seyed N, Eslamifar A, Taghikhani M, Samimi-Rad K, Rafati S.
    Mol Immunol; 2013 Jan 19; 53(1-2):149-60. PubMed ID: 22926003
    [Abstract] [Full Text] [Related]

  • 10. A Genetically Modified attenuated Listeria Vaccine Expressing HPV16 E7 Kill Tumor Cells in Direct and Antigen-Specific Manner.
    Jia YY, Tan WJ, Duan FF, Pan ZM, Chen X, Yin YL, Jiao XA.
    Front Cell Infect Microbiol; 2017 Jan 19; 7():279. PubMed ID: 28706878
    [Abstract] [Full Text] [Related]

  • 11. Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients.
    Bolhassani A, Zahedifard F, Taslimi Y, Taghikhani M, Nahavandian B, Rafati S.
    Indian J Med Res; 2009 Nov 19; 130(5):533-41. PubMed ID: 20090101
    [Abstract] [Full Text] [Related]

  • 12. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
    Granadillo M, Vallespi MG, Batte A, Mendoza O, Soria Y, Lugo VM, Torrens I.
    Vaccine; 2011 Jan 29; 29(5):920-30. PubMed ID: 21145912
    [Abstract] [Full Text] [Related]

  • 13. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
    Jia Y, Yin Y, Duan F, Fu H, Hu M, Gao Y, Pan Z, Jiao X.
    Int J Mol Med; 2012 Dec 29; 30(6):1335-42. PubMed ID: 23027427
    [Abstract] [Full Text] [Related]

  • 14. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.
    Salehi M, Taheri T, Mohit E, Zahedifard F, Seyed N, Taslimi Y, Sattari M, Bolhassani A, Rafati S.
    Immunotherapy; 2012 Nov 29; 4(11):1107-20. PubMed ID: 23194361
    [Abstract] [Full Text] [Related]

  • 15. Immunization of mice by the co-administration of codon-optimized HPV16 E7 and lL12 genes against HPV16-associated cervical cancer.
    Ajorloo M, Alamdary A, Soleimanjahi H, El Boulani A, Khanizadeh S, Nikoo HR.
    Microb Pathog; 2019 Jul 29; 132():20-25. PubMed ID: 31004722
    [Abstract] [Full Text] [Related]

  • 16. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
    Grasso F, Negri DR, Mochi S, Rossi A, Cesolini A, Giovannelli A, Chiantore MV, Leone P, Giorgi C, Cara A.
    Int J Cancer; 2013 Jan 15; 132(2):335-44. PubMed ID: 22700466
    [Abstract] [Full Text] [Related]

  • 17. A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
    Demurtas OC, Massa S, Ferrante P, Venuti A, Franconi R, Giuliano G.
    PLoS One; 2013 Jan 15; 8(4):e61473. PubMed ID: 23626690
    [Abstract] [Full Text] [Related]

  • 18. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S, Zhang W, Hu X, Wang W, Deng D, Wang H, Wang C, Zhou J, Wang S, Zhang H, Ma D.
    Mol Immunol; 2015 Apr 15; 64(2):295-305. PubMed ID: 25575128
    [Abstract] [Full Text] [Related]

  • 19. Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women.
    Ramezani A, Aghakhani A, Soleymani S, Bavand A, Bolhassani A.
    BMC Infect Dis; 2019 Feb 12; 19(1):142. PubMed ID: 30755156
    [Abstract] [Full Text] [Related]

  • 20. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF, Chang MC, Sun WZ, Jen YW, Liao CW, Chen YY, Chen CA.
    PLoS One; 2013 Feb 12; 8(9):e71216. PubMed ID: 24058440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.